Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients

1997 ◽  
Vol 15 (12) ◽  
pp. 1695-1698 ◽  
Author(s):  
Paolo Dessì-Fulgheri ◽  
Riccardo Sarzani ◽  
Paola Tamburrini ◽  
Alessandra Moraca ◽  
Emma Espinosa ◽  
...  
1993 ◽  
Vol 11 (5) ◽  
pp. S479
Author(s):  
Riccardo Sarzani ◽  
P. Dess??-Fulgheri ◽  
V. M. Paci ◽  
Emma Espinosa ◽  
Alessandro Rappelli

Endocrinology ◽  
1995 ◽  
Vol 136 (6) ◽  
pp. 2427-2434 ◽  
Author(s):  
T Yoshimoto ◽  
M Naruse ◽  
K Naruse ◽  
Y Fujimaki ◽  
A Tanabe ◽  
...  

2002 ◽  
Vol 362 (2) ◽  
pp. 231-237 ◽  
Author(s):  
Hugo POIRIER ◽  
Jean LABRECQUE ◽  
Julie DESCHÊNES ◽  
André DeLÉAN

The microbial polysaccharide HS-142-1 has been documented as an antagonist of natriuretic peptides. It inhibits activation and peptide binding to both guanylate receptors natriuretic peptide receptor (NPR)-A and NPR-B, but has no effect on the non-cyclase receptor NPR-C. At first sight the effect of HS-142-1 on peptide binding appears to be surmountable, suggesting that it might be competitive despite its chemically divergent nature. We explored its mode of action on wild-type NPR-A (WT), on a disulphide-bridged constitutively active mutant (C423S) and on truncated mutants lacking either their cytoplasmic domain (ΔKC) or both the cytoplasmic and the transmembrane domains (ECD). On the WT, HS-142-1 inhibited atrial natriuretic peptide (ANP) binding with a pK value of 6.51±0.07 (Kd = 0.31μM). It displayed a similar effect on the C423S mutant (pK = 6.31±0.11), indicating that its action might not be due to interference with receptor dimerization. HS-142-1 also inhibited ANP binding to ΔKC with a pK of 7.05±0.05 (Kd = 0.089μM), but it was inactive on ANP binding to ECD at a concentration of 10−4M, suggesting that the antagonism was not competitive at the peptide-binding site located on the ECD and that the transmembrane domain might be required. HS-142-1 also enhanced dissociation of NPR-A-bound 125I-ANP in the presence of excess unlabelled ANP, implying an allotopic (allosteric) mode of action for the antagonist.


1991 ◽  
Vol 266 (17) ◽  
pp. 11122-11125
Author(s):  
T. Saheki ◽  
T. Mizuno ◽  
T. Iwata ◽  
Y. Saito ◽  
T. Nagasawa ◽  
...  

2001 ◽  
Vol 358 (2) ◽  
pp. 379 ◽  
Author(s):  
Michael F. GOY ◽  
Paula M. OLIVER ◽  
Kit E. PURDY ◽  
Joshua W. KNOWLES ◽  
Jennifer E. FOX ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document